Table 3.
Baseline features of 24 HCC patients enrolled in this study
| Number | Age | Gender | Stage | Diagnosis | HLA-A genotype | Positive T cell response to peptide |
|---|---|---|---|---|---|---|
| #1 | 59 | Male | II | HCC(CHB) | 02:01/11:01 | None |
| #2 | 47 | Male | III | HCC(CHB) | 02:01/30:01 | None |
| #3 | 61 | Female | III | HCC(CHB) | 02:01/02:03 | P8/P10/P13/P23/P25 |
| #4 | 82 | Male | IV | HCC(CHB) | 02:01/11:02 | None |
| #5 | 53 | Male | IV | HCC(CHB) | 02:01/02:06 | None |
| #6 | 51 | Male | III | HCC(CHB) | 02:01/24:02 | None |
| #7 | 43 | Female | IV | HCC(CHB) | 02:01/24:02 | P8/P23 |
| #8 | 71 | Female | III | HCC(CHB) | 02:01/11:01 | P23 |
| #9 | 65 | Male | IV | HCC(CHB) | 02:01/31:01 | None |
| #10 | 51 | Female | III | HCC(CHB) | 02:01/33:03 | None |
| #11 | 57 | Male | IV | HCC(CHB) | 02:01/11:01 | P23 |
| #12 | 67 | Male | III | HCC(CHB) | 02:01/02:06 | None |
| #13 | 50 | Male | IV | HCC(CHB) | 02:01/24:02 | None |
| #14 | 37 | Male | IV | HCC(CHB) | 02:01/02:03 | P10/P13/P23 |
| #15 | 62 | Male | II | HCC(CHB) | 02:01/01:01 | None |
| #16 | 56 | Male | III | HCC(CHB) | 02:01/11:01 | None |
| #17 | 68 | Female | IV | HCC(CHB) | 02:01/24:02 | P23 |
| #18 | 53 | Female | III | HCC(CHB) | 02:01/24:02 | None |
| #19 | 46 | Male | IV | HCC(CHB) | 02:01/11:01 | None |
| #20 | 62 | Male | III | HCC(CHB) | 02:01/33:03 | P13/P23 |
| #21 | 51 | Female | III | HCC(CHB) | 02:01/24:02 | P25 |
| #22 | 56 | Male | IV | HCC(CHB) | 02:01/03:01 | None |
| #23 | 59 | Female | III | HCC(CHB) | 02:01/02:07 | P25 |
| #24 | 64 | Female | IV | HCC(CHB) | 02:01/24:02 | None |
Positive T cell response to peptide: the putative epitope peptides induced positive T cell responses in the IFN-γ Elispot assays in at least two patients’ PBMCs; None: no epitope peptide-induced positive T cell response in the patient’s PBMCs